Security key
74587V107
PUMA BIOTECHNOLOGY, INC. - Common Stock (PBYI)
CUSIP: 74587V107
Q2 2018 13F Holders as of 30 Jun 2018
- Security type / class
- Equity / Common Stock
- Total 13F shares
- 35,935,120
- Total 13F value
- $2,125,191,869
- Share change
- +403,126
- Put/Call ratio
- 97%
- SEC-reported price per share
- $59.15
- Number of holders
- 169
- Value change
- -$1,056,901
- Number of buys
- 91
- Number of sells
- 78
- Shares outstanding
- 49,633,071
Holder snapshot
7 signals
Open additional details 1 more signal available
Security identity
Names, identifiers, and filing context for this profile.
1 source field
Report period
Q2 2018
Institutions
169
Top holders
10
PBYI full security history
Ownership snapshot
Full 13F holder table
Newer quarter: Q3 2018
Previous quarter: Q1 2018
PUMA BIOTECHNOLOGY, INC. SEC filings
PUMA BIOTECHNOLOGY, INC. company facts
Broader feeds
Reporting periods
Holder history for CUSIP 74587V107
Recent filing periods:
Ownership snapshot
Top reported holders of PBYI - PUMA BIOTECHNOLOGY, INC. - Common Stock (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
JANUS HENDERSON GROUP PLC
Disclosed value leader
JANUS HENDERSON GROUP PLC
Comparable rows
15/15
Latest evidence
31 Mar 2018
13F
Lead comparable stake: 9%
Showing 1-6 of 15 holder rows.
Quick read
JANUS HENDERSON GROUP PLC leads the comparable SEC ownership view at 9%.
15 of 15 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens JANUS HENDERSON GROUP PLC's linked filing trail.
Comparable ownership
Top 5
JANUS HENDERSON GROUP PLC
9%
VANGUARD GROUP INC
5.3%
ORBIMED ADVISORS LLC
5.3%
BlackRock Finance, Inc.
4.8%
PFM Health Sciences, LP
4.1%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-6 of 15 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| JANUS HENDERSON GROUP PLC |
13F
Company
|
9%
|
$304,791,000
4,482,306 shares
|
— | 31 Mar 2018 |
| VANGUARD GROUP INC |
13F
Company
|
5.3%
|
$180,318,000
2,649,799 shares
|
— | 31 Mar 2018 |
| ORBIMED ADVISORS LLC |
13F
Company
|
5.3%
|
$179,765,000
2,641,661 shares
|
— | 31 Mar 2018 |
| BlackRock Finance, Inc. |
13F
Company
|
4.8%
|
$161,258,000
2,369,714 shares
|
— | 31 Mar 2018 |
| PFM Health Sciences, LP |
13F
Company
|
4.1%
|
$138,320,000
2,032,619 shares
|
— | 31 Mar 2018 |
| FMR LLC |
13F
Company
|
3.2%
|
$108,069,000
1,588,089 shares
|
— | 31 Mar 2018 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
13F holder rows
Institutional holders as of Q2 2018
Investor-level positions for this CUSIP, loaded as an interactive table.
Institutions
169
Shares
35,935,120
Rows available
169
| Investor | Option | Weight % | Change % | SEC-reported value | * Price | Shares | Share Change | Activity | Report Period |
|---|
* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.
Compare Q2 2018 vs Q1 2018 Across Filers
Q1 2018 holders
168
Q2 2018 holders
169
Holder diff
1
| Investor | Q1 2018 Shares | Q2 2018 Shares | Share Diff | Share Chg % | Q1 2018 value | Q2 2018 value | Value change | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend